This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Published Sep 22, 2026 15:46 UTC |

Translation unavailable. Please try again.

What the source reports

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

No specific asset was identified in this report; browse live USDT reference pairs.